Lamotrigine/sertraline

Drug Profile

Lamotrigine/sertraline

Alternative Names: 15/30-SER-LAM; 30/15-LAM/SER; LAM/SER; SER/LAM; Sertraline/lamotrigine

Latest Information Update: 08 Apr 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Meditop Pharmaceutical
  • Class Amines; Analgesics; Naphthalenes; Small molecules; Triazines
  • Mechanism of Action Serotonin uptake inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Back pain

Most Recent Events

  • 16 Dec 2014 Meditop Pharmaceutical completes a phase II trial in Back pain in Hungary (EudraCT2013-004564-55)
  • 12 Jun 2014 Phase-II clinical trials in Back pain in Romania (PO) (EudraCT2013-004564-55)
  • 10 Mar 2014 Phase-II clinical trials in Back pain in Hungary (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top